The Valley Desk

ArticleJournal of comparative effectiveness researchPublished

Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of comparative effectiveness research
Published
Subject terms
Humans; Neoplasm Metastasis; Thiohydantoins; Retrospective Studies; Aged; Aged, 80 and over; Middle Aged; United States; Male; Androgen Receptor Antagonists; Prostatic Neoplasms, Castration-Resistant; Abiraterone Acetate
PubMed ID
40340441
PubMed Central ID
PMC12224120
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal